Trial Profile
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Amlodipine; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Sep 2017 Results published in the European Heart Journal.
- 16 Nov 2016 Results assessing effects of LCZ696 on LV-structure and function as well as on regional and global aortic distensibility, presented at the 89th Annual Scientific Sessions of the American Heart Association
- 13 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.